Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Concludes Entire Antiepileptic Category Poses Suicidality Risk

Executive Summary

FDA is concluding from its statistical analysis of suicidality for antiepileptic drugs that the entire therapeutic category poses an increased risk of suicidal behavior or ideation. But there may be a silver lining for sponsors within the data

You may also be interested in...



Boxed Warning Too Strong For Anti-Epileptic Suicidality Signal, Cmte. Says

While advisory committee members agreed that chronically used anti-epileptic drugs show a signal for suicidality, a majority of the panelists felt a class-wide "black box" warning is too strong to convey the risk

Boxed Warning Too Strong For Anti-Epileptic Suicidality Signal, Cmte. Says

While advisory committee members agreed that chronically used anti-epileptic drugs show a signal for suicidality, a majority of the panelists felt a class-wide "black box" warning is too strong to convey the risk

Antiepileptics Show Risk Of Suicidality, May Cause Labeling Convulsions

FDA findings of an increased risk of suicidality in patients given antiepileptic drugs will likely lead to broad class labeling changes, according to a MedWatch alert issued Jan. 31

Related Content

UsernamePublicRestriction

Register

PS049813

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel